Aptevo Therapeutics Inc.
APVONASDAQHealthcareBiotechnology
Previous close
$2.68
−$0.0776 · -2.81%
Pre-market
$2.73
+$0.05 · +1.87%
Aug 24, 4:00 AM ET
APVO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Momentum
24
Weakening
Sentiment
56
Mixed
Risk resilience
22
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jeffrey G. Lamothe
- Listed since
- Jul 20, 2016
- Employees
- 33
Market position
Day range
Current $2.68
52-week range
Current $2.68
- Open
- $2.84
- Previous close
- $2.7576
- Volume
- 53.27K
- 1.09× average
- Average volume
- 49.07K
- Average daily volume
- Market cap
- 5.86M USD
- Beta
- 1.65
- Market reference 1
- 50-day average
- $4.1765
- -35.83% below average
- 200-day average
- $8.6081
- -68.87% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -16.94M USD
- P/E (TTM)
- -0.01×
- P/B (TTM)
- 0.53×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.66×
- Earnings yield
- -87279.19%
- Free cash flow yield
- -86018.76%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -149.40%
- Return on assets
- -95.49%
- Return on invested capital
- -119.55%
Financial health
- Debt / equity
- 0.7×
- Current ratio
- 3.82×
- Altman Z-score
- -32.96
- Piotroski F-score
- 1 of 9
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -5261.99%
- 11 comparable reports
- Latest EPS result
- -5.31
- Estimate -6.02 · Beat by 11.79%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
APVO news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 30, 2025 | 1:18 | — | — |
Stock split | May 27, 2025 | 1:20 | — | — |
Stock split | Dec 4, 2024 | 1:37 | — | — |
Stock split | Mar 6, 2024 | 1:44 | — | — |
Stock split | Mar 27, 2020 | 1:14 | — | — |
Effective Dec 30, 2025
1:18
Effective May 27, 2025
1:20
Effective Dec 4, 2024
1:37
Effective Mar 6, 2024
1:44
Effective Mar 27, 2020
1:14
APVO peers
ETFs holding APVO
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research APVOresearch.disclaimer